There were 2,204 press releases posted in the last 24 hours and 360,089 in the last 365 days.

Cardio Vascular Medical Device To Split 1-For-3

December 3, 2009 (FinancialWire) — Cardio Vascular Medical Device Corp. (OTCBB: CVSL), a developer of cardiovascular surgery technology, said its board has approved a one-for-three forward stock split, in the form of a stock dividend, payable to Cardio Vascular Medical Device shareholders.

When the forward stock split becomes effective, shareholders of common stock will receive an additional two shares for each share held at the record date.

Israel-based Cardio Vascular Medical Device holds a US patent for a “steerable guidewire” applicable for all angioplasty procedures.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports, filings and conference call webcasts for companies mentioned in the news are available via Investrend Syndications (http://investrend.ar.wilink.com/?level=279). The most recently issued reports and/or recorded webcasts include Cascade Corp. (NYSE: CASC), Anadarko Petroleum Corp. (NYSE: APC), Baytex Energy Trust (NYSE: BTE) (TSX: BTE), H & Q Healthcare Investors (NYSE: HQH), H & Q Life Science Investors (NYSE: HQL), PIMCO (NYSE: PYN) (NYSE: PMX) (NYSE: PZC), PIMCO Global StocksPLUS & Income Fund (NYSE: PGP), Taiwan Greater China Fund (NYSE: TFC) and Wolseley PLC (OTC: WOSCF) (London Stock Exchange: WOS).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.